Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EBITDA: 2019-2024

Historic EBITDA for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to -$49.2 million.

  • Compass Therapeutics' EBITDA fell 43.31% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.0 million, marking a year-over-year decrease of 40.93%. This contributed to the annual value of -$49.2 million for FY2024, which is 16.72% down from last year.
  • Per Compass Therapeutics' latest filing, its EBITDA stood at -$49.2 million for FY2024, which was down 16.72% from -$42.2 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' EBITDA registered a high of -$32,105 during FY2020, and its lowest value of -$82.2 million during FY2021.
  • Moreover, its 3-year median value for EBITDA was -$42.2 million (2023), whereas its average is -$43.6 million.
  • As far as peak fluctuations go, Compass Therapeutics' EBITDA plummeted by 195.49% in 2021, and later soared by 51.90% in 2022.
  • Yearly analysis of 5 years shows Compass Therapeutics' EBITDA stood at -$32,105 in 2020, then grew by 18.32% to -$27.8 million in 2020, then slumped by 195.49% to -$82.2 million in 2021, then surged by 51.90% to -$39.5 million in 2022, then dropped by 6.65% to -$42.2 million in 2023, then dropped by 16.72% to -$49.2 million in 2024.